CASE REPORT article
Front. Oncol.
Sec. Gastrointestinal Cancers: Colorectal Cancer
Biweekly TAS-102 and Bevacizumab as Maintenance Therapy for Recurrent and Metastatic Pseudomyxoma Peritonei Following Palliative Cytoreduction
Provisionally accepted
- 1Jinan Central Hospital, Jinan, China
- 2Department of Endocrinology, Shandong First Medical University, Jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction:Recurrence of pseudomyxoma peritonei (PMP) with pulmonary and lymphatic metastases occurs only rarely in clinical practice, making the selection of an appropriate postoperative chemotherapy regimen essential for managing these complex cases. Case Presentation:We describe an 83-year-old woman with an appendiceal pseudomucinous tumor who developed a recurrence two years after initial surgery, presenting with bilateral lung metastases and multiple lymph node metastases. Palliative cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) was performed to relieve intestinal obstruction. Given the patient's advanced age and the complexity of the procedure, the completeness of cytoreduction score was 2 and the peritoneal cancer index (PCI) was 10. Postoperative pathology confirmed a high-grade mucinous adenocarcinoma of appendiceal origin. After initiating a biweekly regimen of trifluridine/tipiracil (TAS-102) combined with bevacizumab, the patient achieved disease stabilization for approximately five months, with stable tumor marker levels and no evidence of radiological progression. Conclusion:This case underscores the therapeutic challenges of recurrent PMP with bilateral pulmonary and multiple lymph node metastases. A biweekly regimen of TAS-102 plus bevacizumab may represent a viable maintenance option when surgery and conventional chemotherapy regimens prove unsatisfactory.
Keywords: Pseudomyxoma peritonei (PMP), Preoperative preparation, Pulmonary metastasis, Lymphatic Metastasis, Chemotherapy regimen
Received: 19 May 2025; Accepted: 30 Oct 2025.
Copyright: © 2025 Wang, Wang, Yu, Jiao, Zhao, Zhang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Bao Xuan Wang, 1350062847@qq.com
Guanying Yu, ygy1608@zxyy.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.